Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus.


Journal

Diabetes & metabolism
ISSN: 1878-1780
Titre abrégé: Diabetes Metab
Pays: France
ID NLM: 9607599

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 22 08 2023
revised: 30 08 2023
accepted: 04 09 2023
medline: 27 11 2023
pubmed: 15 9 2023
entrez: 14 9 2023
Statut: ppublish

Résumé

We examined whether different insulin administration modalities, i.e., multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII by insulin pumps), are differently associated with the risk of having metabolic dysfunction-associated fatty liver disease (MAFLD), with or without coexisting significant liver fibrosis (assessed by validated non-invasive biomarkers), in adults with type 1 diabetes mellitus (T1DM). We conducted a retrospective, multicenter, cross-sectional study involving 1,417 adult individuals with established T1DM treated with MDI or CSII. We calculated hepatic steatosis index (HSI) and fibrosis (FIB)-4 index for non-invasively detecting MAFLD (defined by HSI >36), with or without coexisting significant fibrosis (defined by FIB-4 index ≥ 1.3 or <1.3, respectively). Compared to the MDI group (n = 1,161), insulin-pump users (n = 256; 18.1%) were more likely to be younger (mean age: 40 vs. 48 years, P < 0.001), had better glycemic control (mean hemoglobin A1c: 7.7%  vs. 7.9%, P = 0.025) and a markedly lower prevalence of MAFLD with coexisting significant fibrosis (2.7%  vs. 8.1%, P = 0.010), but a comparable prevalence of MAFLD without fibrosis. In multinomial logistic regression analysis, CSII therapy was associated with a ∼70%-lower risk of MAFLD with significant fibrosis (unadjusted odds ratio 0.32, 95% confidence interval 0.14-0.70; P = 0.004), but this association was no longer significant after adjustment for age, hemoglobin A1c and other potential confounders. The lower prevalence of MAFLD with coexisting significant fibrosis we observed in adults with T1DM using CSII therapy, compared to those using MDI therapy, is primarily mediated by inter-group differences in age.

Identifiants

pubmed: 37708990
pii: S1262-3636(23)00059-9
doi: 10.1016/j.diabet.2023.101477
pii:
doi:

Substances chimiques

Glycated Hemoglobin 0
Insulin 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101477

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Alessandro Csermely (A)

Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy.

Alessandro Mantovani (A)

Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy.

Mario Luca Morieri (ML)

Metabolic Diseases, Department of Medicine, University of Padua, Padua, Italy.

Luisa Palmisano (L)

Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.

Maria Masulli (M)

Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.

Efisio Cossu (E)

Diabetology Unit, Policlinico Universitario of Cagliari, Cagliari, Italy.

Marco Giorgio Baroni (MG)

Department of Clinical Medicine, Life, Health and Environmental Sciences, University of Aquila, L'Aquila, Italy; Neuroendocrinology and Metabolic Diseases, IRCCS Neuromed, Pozzilli, Italy.

Katia Bonomo (K)

Diabetes and Metabolic Diseases Unit, San Luigi Gonzaga University Hospital, Turin, Italy.

Flavia Agata Cimini (FA)

Department of Experimental Medicine, Sapienza University, Rome, Italy.

Gisella Cavallo (G)

Department of Experimental Medicine, Sapienza University, Rome, Italy.

Raffaella Buzzetti (R)

Department of Experimental Medicine, Sapienza University, Rome, Italy.

Carmen Mignogna (C)

Department of Experimental Medicine, Sapienza University, Rome, Italy.

Frida Leonetti (F)

Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, Rome, Italy.

Simonetta Bacci (S)

Section of Endocrinology, Department of Medicine, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy.

Roberto Trevisan (R)

Department of Medicine and Surgery, University of Milan Bicocca, Milan, Italy.

Riccardo Maria Pollis (RM)

Metabolic Diseases, Department of Medicine, University of Padua, Padua, Italy.

Raffaella Aldigeri (R)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Alessandra Dei Cas (AD)

Department of Medicine and Surgery, University of Parma, Parma, Italy; Division of Nutritional and Metabolic Sciences, Azienda Ospedaliero-Universitaria, Parma, Italy.

Saula Vigili de Kreutzenberg (SV)

Metabolic Diseases, Department of Medicine, University of Padua, Padua, Italy.

Giovanni Targher (G)

Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy; Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella, Italy. Electronic address: giovanni.targher@univr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH